Literature DB >> 29763637

Neurosteroid pregnenolone sulfate, alone, and as augmentation of lurasidone or tandospirone, rescues phencyclidine-induced deficits in cognitive function and social interaction.

L Rajagopal1, D Soni1, H Y Meltzer2.   

Abstract

BACKGROUND: Pregnenolone sulfate (PregS), an endogenous neurosteroid, which negatively and positively modulates gamma amino butyric acid subunit A (GABAA) and N-methyl D-aspartate (NMDA) receptors (R) respectively, among other potential neuroplastic changes on synaptic processes, has shown some beneficial effects on treating cognitive impairment associated with schizophrenia (CIAS) and negative symptoms. Lurasidone (Lur), an atypical antipsychotic drug (AAPD), and tandospirone (Tan), a 5-HT1A R partial agonist, have also been reported to improve cognitive or negative symptoms, or both, in some schizophrenia patients.
METHODS: We tested whether PregS, by itself, and in combination with Lur or Tan could rescue persistent deficits produced by subchronic treatment with the NMDAR antagonist, phencyclidine (PCP)-in episodic memory, executive functioning, and social behavior, using novel object recognition (NOR), operant reversal learning (ORL), and social interaction (SI) tasks, in male C57BL/6 J mice.
RESULTS: PregS (10, but not 3 mg/kg) significantly rescued subchronic PCP-induced NOR and SI deficits. Co-administration of sub-effective doses (SEDs) of PregS (3 mg/kg) + Lur (0.1 mg/kg) or Tan (0.03 mg/kg) rescued scPCP-induced NOR and SI deficits. Further, PregS (30, but not 10 mg/kg) rescued PCP-induced ORL deficit, as did the combination of SED PregS (10 mg/kg) +SED Lur (1 mg/kg) or Tan (1 mg/kg).
CONCLUSION: PregS was effective alone and as adjunctive treatment for treating two types of cognitive impairments and negative symptoms in this schizophrenia model. Further study of the mechanisms by which PregS alone and in combination with AAPDs and 5-HT1A R partial agonists, rescues the deficits in cognition and SI in this preclinical model is indicated.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  GABA; Glutamate; Lurasidone; Neurosteroid; Phencyclidine; Pregnenolone sulfate; Tandospirone

Mesh:

Substances:

Year:  2018        PMID: 29763637     DOI: 10.1016/j.bbr.2018.05.005

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  9 in total

1.  5-HT1A parital agonism and 5-HT7 antagonism restore episodic memory in subchronic phencyclidine-treated mice: role of brain glutamate, dopamine, acetylcholine and GABA.

Authors:  Mei Huang; Sunoh Kwon; Lakshmi Rajagopal; Wenqi He; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2018-07-31       Impact factor: 4.530

2.  Contrasting Typical and Atypical Antipsychotic Drugs.

Authors:  Herbert Y Meltzer; Erick Gadaleta
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

3.  TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABAA receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia.

Authors:  Lakshmi Rajagopal; Mei Huang; Eric Michael; Sunoh Kwon; Herbert Y Meltzer
Journal:  Neuropsychopharmacology       Date:  2018-07-23       Impact factor: 7.853

4.  Quercetin Reduces Cortical GABAergic Transmission and Alleviates MK-801-Induced Hyperactivity.

Authors:  Hui-Ran Fan; Wei-Feng Du; Tao Zhu; Yan-Jiao Wu; Yan-Mei Liu; Qi Wang; Qin Wang; Xue Gu; Xingyue Shan; Shining Deng; Tailin Zhu; Tian-Le Xu; Wei-Hong Ge; Wei-Guang Li; Fei Li
Journal:  EBioMedicine       Date:  2018-07-26       Impact factor: 8.143

5.  Neuropsychiatric phenotype in relation to gene variants in the hemizygous allele in 3q29 deletion carriers: A case series.

Authors:  Eva Albertsen Malt; Katalin Juhasz; Anna Frengen; Teresia Wangensteen; Nina Merete Emilsen; Borre Hansen; Oleg Agafonov; Hilde Loge Nilsen
Journal:  Mol Genet Genomic Med       Date:  2019-07-25       Impact factor: 2.183

6.  EEG power spectral analysis reveals tandospirone improves anxiety symptoms in patients with Alzheimer's disease: a prospective cohort study.

Authors:  Zhengluan Liao; Xiaoyu Zhao; Ting Li; Yanping Mao; Jiaojiao Hu; Dansheng Le; Yangliu Pei; Yan Chen; Yaju Qiu; Junpeng Zhu; Jixin Lin; Heng Su; Linju Zhang; Enyan Yu
Journal:  Ann Transl Med       Date:  2021-01

7.  Urinary metabolic phenotyping for Alzheimer's disease.

Authors:  Natalja Kurbatova; Manik Garg; Luke Whiley; Elena Chekmeneva; Beatriz Jiménez; María Gómez-Romero; Jake Pearce; Torben Kimhofer; Ellie D'Hondt; Hilkka Soininen; Iwona Kłoszewska; Patrizia Mecocci; Magda Tsolaki; Bruno Vellas; Dag Aarsland; Alejo Nevado-Holgado; Benjamine Liu; Stuart Snowden; Petroula Proitsi; Nicholas J Ashton; Abdul Hye; Cristina Legido-Quigley; Matthew R Lewis; Jeremy K Nicholson; Elaine Holmes; Alvis Brazma; Simon Lovestone
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

8.  Depolarizing GABAA current in the prefrontal cortex is linked with cognitive impairment in a mouse model relevant for schizophrenia.

Authors:  Haram R Kim; Lakshmi Rajagopal; Herbert Y Meltzer; Marco Martina
Journal:  Sci Adv       Date:  2021-03-31       Impact factor: 14.136

9.  Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia.

Authors:  Herbert Y Meltzer; Daniel B Share; Karu Jayathilake; Ronald M Salomon; Myung A Lee
Journal:  J Clin Psychopharmacol       Date:  2020 May-Jun       Impact factor: 3.118

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.